BioSpace News Archive

Business

Novartis, Biogen Scrap Gene Regulation Partnerships with Sangamo

Sangamo Therapeutics lost two powerhouse partners Friday after it reported that both Novartis and Biogen discontinued focusing on gene regulation therapies in the neurology space.

March 20, 2023
·
2 min read
·
Tristan Manalac
Business

Raises for Moderna, Pfizer CEOs Highlight Continuing Trend

As demand for biotech talent increases, the need to offer competitive pay to the average employee puts financial pressure on companies to increase CEO pay as well.

March 20, 2023
·
2 min read
·
Jia Jie Chen
Drug Development

FDA Releases Briefing Docs for Upcoming Biogen/Ionis Tofersen Adcomm

Biomarkers as a surrogate endpoint in ALS will go on trial on March 22 as Biogen and Ionis’s tofersen faces the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee.

March 20, 2023
·
5 min read
·
Heather McKenzie
Drug Development

Takeda’s $4B Plaque Psoriasis Candidate Clears Mid-Stage Study

Takeda will advance its experimental drug for plaque psoriasis, TAK-279, to Phase III later this year after the TYK2 inhibitor met its primary and secondary endpoints in a Phase IIb study.

March 20, 2023
·
1 min read
·
Ana Mulero
Drug Development

Karuna’s KarXT Aces Third Registrational Study in Schizophrenia

Karuna Therapeutics released data Monday from the Phase III EMERGENT-3 trial showing that KarXT met the primary endpoint, significantly improving symptom severity.

March 20, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors

Allarity Therapeutics, Inc. announced that it has dosed the first patient in a Phase 1b clinical study evaluating the combination of stenoparib and dovitinib for the treatment of advanced solid tumors, including ovarian cancer.

March 20, 2023
·
10 min read
WuXi AppTec Reports Record Results in 2022

WuXi AppTec is pleased to announce its annual results for the year ending December 31, 2022.

March 20, 2023
·
26 min read
Genetown

SpyBiotech Receives Grant to Advance Novel SpyVector Platform That Improves Efficacy and Boosting Capability of Adenovirus-based Vaccines Against Current and Future Pandemic Viruses

SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has received a grant of $4,094,561 from the Bill & Melinda Gates Foundation to further develop its novel SpyVector platform.

March 20, 2023
·
2 min read
Lone Star Bio

Vizient to Share Insights on Biosimilars at Festival of Biologics

Vizient, Inc. announced today that Steven Lucio, PharmD, BCPS, senior principal, pharmacy solutions for Vizient, will share insights on biosimilars in the panel discussion, “Building the Sustainable Future of Biosimilars,” at the Festival of Biologics being held March 20-22 in San Diego.

March 20, 2023
·
1 min read
Drug Development

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

Karuna Therapeutics, Inc. announced positive topline results from its Phase 3 EMERGENT-3 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT in adults with schizophrenia.

March 20, 2023
·
9 min read